A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI